DS
JBIO

David Shaw’s Jade Biosciences JBIO Stock Holding History

David Shaw’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14M Buy
+51,494
New +$1.07M ﹤0.01% 3658
2024
Q2 		– Sell
-493
Closed -$511K – 4477
2024
Q1 		$511K Buy
+493
New +$377K ﹤0.01% 3476
2023
Q2 		– Sell
-456
Closed -$322K – 4224
2023
Q1 		$322K Sell
456
-387
-46% -$321K ﹤0.01% 3730
2022
Q4 		$864K Sell
843
-137
-14% -$99.5K ﹤0.01% 3542
2022
Q3 		$569K Buy
+980
New +$654K ﹤0.01% 3963

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

David Shaw's JBIO Position: Q2 2026 in Review

David Shaw opened a new position in Jade Biosciences (JBIO) in Q2 2026: 51,494 shares worth $1.14M. The stake represents ﹤0.01% of the portfolio and ranks #3658 among its holdings. This is a return to the name: David Shaw previously reported a position in JBIO as recently as Q1 2024.

David Shaw first reported a position in JBIO in Q3 2022 and has held it in 5 quarters since. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • David Shaw held 51,494 shares of Jade Biosciences worth $1.14M as of Q2 2026.
  • Jade Biosciences was a new David Shaw position in Q2 2026.
  • Jade Biosciences made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3658 holding.
  • David Shaw first reported a position in Jade Biosciences in Q3 2022 and has held it in 5 quarters since.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.